Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 35,388 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Healthy Subjects
Interventions: Quizartinib, Placebo; Drug · Other
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Knee, ACL
Interventions: Standard Physical Therapy, Ermi Knee Extensionater; Behavioral · Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 14 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Opioid Use Disorder
Interventions: RBP-6000, SUBOXONE Sublingual Film; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Allogeneic Hematopoietic Cell Transplantation
Interventions: Alemtuzumab; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Weeks to 30 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Mechanical Neck Pain
Interventions: Manipulation; Procedure
Lead sponsor: University of Nevada, Las Vegas; Other
Eligibility: 18 Years to 60 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: HIV Prevention
Interventions: Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel, Universal HEC Placebo Gel Formulation; Drug
Lead sponsor: Ian McGowan; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 2
States / cities: Los Angeles, California • Pittsburgh, Pennsylvania

Conditions: Sleep Architecture, Mild Traumatic Brain Injury, Sleep, Sleep and Circadian Problems
Interventions: Cognitive behavioral Therapy for insomnia (CBT-I); Behavioral
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis
Interventions: TruGraf®; Diagnostic Test
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: St Louis, Missouri

Conditions: Hiv, Chlamydia, Gonorrhea
Interventions: 2GETHER, Existing Public Health Practice; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Macular Degeneration
Interventions: Rituximab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 41 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cognitive Impairments, Schizotypal Personality Disorder
Interventions: DAR-0100A, Placebo; Drug
Lead sponsor: Larry J. Siever; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Participants
Interventions: IVX-A12, Licensed RSV Vaccine; Biological
Lead sponsor: Icosavax, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 5
States / cities: Anaheim, California • Rolling Hills Estates, California • Hollywood, Florida + 2 more

Conditions: Healthy Volunteers
Interventions: Teduglutide, Syringe Injection, Pen injector; Drug · Device
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Neoplasms, Malignant, Breast Neoplasm, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasm, Head and Neck Neoplasms
Interventions: Carlo Erba Ink Injection, EPR Oximetry Measurement; Device · Other
Lead sponsor: Philip Schaner; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Pharmacokinetic Study in Healthy Participants
Interventions: Dasatinib as tablets, Dasatinib as liquid, Dasatinib as dispersed tablets; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Breast Cancer
Interventions: IPI-504; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Boca Raton, Florida • Lake Worth, Florida + 3 more

Conditions: Chronic Hepatitis C, Hepatitis C Virus (HCV) Infection
Interventions: ABT-267, Pegylated interferon (pegIFN), Ribavirin (RBV), Placebo for ABT-267; Drug · Other
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 7 more

Conditions: Healthy
Interventions: intranasal ketamine; Drug
Lead sponsor: Javelin Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Arthritis, Gouty
Interventions: canakinumab, dexamethasone, placebo matching canakinumab, placebo matching dexamethasone; Biological · Drug · Other
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Birmingham, Alabama • New Brunswick, New Jersey

Conditions: Epilepsy, Seizures
Interventions: Transcranial Direct Current Stimulation; Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Clostridium Difficile Infection
Interventions: SER-262, Placebo; Drug
Lead sponsor: Seres Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 22
States / cities: Athens, Alabama • Fountain Valley, California • La Mesa, California + 19 more

Conditions: Anaplastic Astrocytoma, Recurrent Anaplastic Astrocytoma
Interventions: Eflornithine, Lomustine; Drug
Lead sponsor: Orbus Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 37 more

Conditions: Tongue Neoplasms, Tongue Cancer, Oral Cancer
Interventions: Palatal Augmentation Prosthesis (PAP), Articulation Therapy; Device · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Suicide
Interventions: Phone call, Text messaging, Automated interactive smartphone-based tool, Non-interactive pop-up messages; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Study to Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate

Restoration of Knee Extension After ACL Reconstruction

Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder

Precision Dosing of Alemtuzumab

Development of a Clinical Prediction Rulefor Neck Manipulation

A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally

Evaluation of Cognitive Behavioral Therapy for Insomnia (CBT-I) in Individuals With Mild Traumatic Brain Injury (mTBI)

TruGraf Liver Gene Expression Serial Test

Online HIV Prevention for Young Male Couples

Treatment -Resistant Neovascular Age-Related Macular Degeneration

Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder

A Study of IVX-A12 in Adults Participants

A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants

EPR Tumor Oximetry With CE India Ink

Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations

A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer

Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Absolute Bioavailability and Nasopharyngeal Absorption of Intranasal Ketamine

Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout

Closed-loop System Using Transcranial Direct Current Stimulation (tDCS) for Epilepsy

SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients

Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue

Just-in-time Interventions for Reducing Short-term Suicide Risk